Oscar Castro
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1093743288
Payments from drug & device makers
Across 126 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$311
- AstraZeneca$309
- Novo Nordisk$239
- Mannkind Corporation$219
- Amgen$215
- Lilly USA, LLC$117
- plus $747 from 21 others
What the payments were for
- Food & beverage$2,13799%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 15 | $311 |
| AstraZeneca | 10 | $309 |
| Novo Nordisk | 20 | $239 |
| Mannkind Corporation | 14 | $219 |
| Amgen(2 entities) | 10 | $215 |
| Lilly USA, LLC | 10 | $117 |
| Merck | 11 | $117 |
| AbbVie | 4 | $83 |
| Pfizer | 2 | $68 |
| Insulet Corporation | 3 | $63 |
| Medtronic | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Tandem Diabetes Care, Inc. | 3 | $45 |
| BETA Bionics, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $29 |
| Novartis | 1 | $27 |
| Antares Pharma, Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| BD | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Cequr Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$120
How this compares
$2,157 in reported general payments places this provider in the 20th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 256 | $290,652 |
| MounjaroTirzepatide | 102 | $119,856 |
| FarxigaDapagliflozin Propanediol | 115 | $103,272 |
| TrulicityDulaglutide | 58 | $73,832 |
| JardianceEmpagliflozin | 67 | $69,569 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $36,627 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $35,733 |
| Novolog FlexpenInsulin Aspart | 70 | $28,163 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $27,303 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $26,125 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $25,449 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $22,922 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $11,496 |
| Gvoke Hypopen 2-PackGlucagon | 12 | $11,159 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $239 | $295,095271 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $117 | $198,309179 claims |
| AstraZenecaFarxiga | $309 | $103,272115 claims |
| Boehringer IngelheimJardiance, Glyxambi | $29 | $81,06580 claims |
| AbbVieSynthroid | $83 | $1,00019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Mobile
- Wilburn BoltonMobile$52K
- Anita KemmerlyMobile$13K
- Michael DavisMobile$12K
- Heather FishelMobile$11K
- Michael GalitzMobile$10K
- Jocelyn HewittMobile$9K
- Huey McDanielMobile$8K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.